IL17A and type 2 diabetes mellitus: We found that at the end of treatment, XOMA052 was able to alleviate chronic inflammation in type 2 diabetes by down-regulating the production of IFN-γ and IL-17a in peripheral blood, reducing inflammatory cytokines TNF-α, IL-1β, and IL-6, and reducing β cell apoptosis and promoting proliferation.